Julianna Merten, PharmD, BCPS, BCOP, of Mayo Clinic provides an overview of growth factor biosimilars for pharmacists amid the pandemic.
In an educational program, Julianna Merten, PharmD, BCPS, BCOP, reviews changes in practice necessitated by coronavirus disease 2019 (COVID-19) and how these affect adherence to national guidelines for the appropriate use of oncology supportive care growth factor biosimilars. This interactive program entitled "Use of Oncology Supportive Care Biosimilars During COVID-19: Clinical Strategies for Pharmacists" features an emphasis on use of these agents for treatment of neutropenia, alternative approaches to care, and economic considerations. The program is available now thorugh July 15, 2021.
Where clinical, regulatory, and economic perspectives converge—sign up for Center for Biosimilars® emails to get expert insights on emerging treatment paradigms, biosimilar policy, and real-world outcomes that shape patient care.